Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 507

1.

Blood and Dietary Magnesium Levels are not linked with lower Prostate Cancer Risk in Black or White Men.

Fowke JH, Koyama T, Dai Q, Zheng SL, Xu J, Howard LE, Freedland SJ.

Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30101-6. doi: 10.1016/j.canlet.2019.02.023. [Epub ahead of print]

PMID:
30776477
2.

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2019 Feb 14:1-5. doi: 10.1080/21681805.2018.1551244. [Epub ahead of print]

PMID:
30762450
3.

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Jan 30. doi: 10.1007/s10552-019-1133-5. [Epub ahead of print]

PMID:
30701374
4.

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Jan 21. doi: 10.1038/s41391-019-0126-5. [Epub ahead of print]

PMID:
30664736
5.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Jan 3. doi: 10.1001/jamaoncol.2018.5904. [Epub ahead of print]

PMID:
30605213
6.

Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2018 Dec 28. pii: S1078-1439(18)30496-4. doi: 10.1016/j.urolonc.2018.12.004. [Epub ahead of print]

PMID:
30598238
7.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

PMID:
30478421
8.

Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):1005. doi: 10.1111/iju.13861. Epub 2018 Nov 20. No abstract available.

PMID:
30458585
9.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
10.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2018 Oct 26. doi: 10.1038/s41391-018-0103-4. [Epub ahead of print]

PMID:
30367117
11.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
12.

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2018 Oct 22. doi: 10.1111/bju.14594. [Epub ahead of print]

PMID:
30347135
13.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [Epub ahead of print]

PMID:
30321406
14.

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0095-0. [Epub ahead of print]

PMID:
30279582
15.

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.

PMID:
30253446
16.

Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):77-83. doi: 10.1038/s41391-018-0090-5. Epub 2018 Sep 13.

PMID:
30214036
17.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary.

Bekelman JE, Rumble RB, Freedland SJ.

J Oncol Pract. 2018 Oct;14(10):618-624. doi: 10.1200/JOP.18.00434. Epub 2018 Sep 10. No abstract available.

PMID:
30199312
18.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ.

J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606. [Epub ahead of print]

PMID:
30183466
19.

Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?

Allott EH, Freeman MR, Freedland SJ.

Eur Urol. 2018 Dec;74(6):702-703. doi: 10.1016/j.eururo.2018.08.012. Epub 2018 Aug 31. No abstract available.

PMID:
30177293
20.

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH.

Cancer Prev Res (Phila). 2018 Oct;11(10):621-628. doi: 10.1158/1940-6207.CAPR-18-0057. Epub 2018 Aug 23.

PMID:
30139875

Supplemental Content

Loading ...
Support Center